Drug Profile


Alternative Names: Arava; HWA 486; SU 101

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Pfizer
  • Class Antineoplastics; Disease-modifying antirheumatics; Isoxazoles; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Dihydropteroate synthase inhibitors; Epidermal growth factor receptor antagonists; Immunomodulators; Immunosuppressants; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriatic arthritis; Rheumatoid arthritis
  • Discontinued Anaplastic astrocytoma; Autoimmune disorders; Cytomegalovirus infections; Glioblastoma; Graft-versus-host disease; Hypersensitivity; Immune-mediated uveitis; Multiple sclerosis; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Psoriasis; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Oct 2015 Generic equivalent available in USA for Rheumatoid arthritis
  • 26 Sep 2013 added SU101 to synonyms
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top